In vitro Activity of Cefmenoxime, Cefotaxime, Latamoxef, Cefazolin, Nafcillin and Vancomycin against 53 Endocarditis and Bacteremic Strains of Staphylococcusaureus
- 1 January 1984
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 30 (5) , 328-330
- https://doi.org/10.1159/000238288
Abstract
Antistaphylococcal activity of newer β-lactam antibiotics, cefmenoxime, cefotaxime and latamoxef was compared with that of the more conventional antistaphylococcal agents, nafcillin, cefazolin and vancomycin. 53 strains of Staphylococcus aureus, 40 from patients with endocarditis and 13 from patients with bacteremia from other causes were tested in vitro against each antibiotic using agar dilution methods. Minimal concentration of antibiotic to inhibit 90% of strains tested was 2 μg/ml for cefmenoxime and cefotaxime, 8 μg/ml for latamoxef and only 0.5 μg/ml for nafcillin, cefazolin and vancomycin. The newer β-lactam antibiotics may not be preferred to nafcillin, cefazolin or vancomycin in the treatment of serious staphylococcal infections.Keywords
This publication has 2 references indexed in Scilit:
- Susceptibility of Gram-Positive Cocci to Various Antibiotics, Including Cefotaxime, Moxalactam, and N -Formimidoyl ThienamycinAntimicrobial Agents and Chemotherapy, 1981
- Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activitiesAntimicrobial Agents and Chemotherapy, 1981